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Advances in neuroscience identified addiction as a chronic brain disease with strong genetic, neu-
rodevelopmental, and sociocultural components. We here discuss the circuit- and cell-level mech-
anisms of this condition and its co-option of pathways regulating reward, self-control, and affect.
Drugs of abuse exert their initial reinforcing effects by triggering supraphysiologic surges of dopa-
mine in the nucleus accumbens that activate the direct striatal pathway via D1 receptors and inhibit
the indirect striato-cortical pathway via D2 receptors. Repeated drug administration triggers neuro-
plastic changes in glutamatergic inputs to the striatum andmidbrain dopamine neurons, enhancing
the brain’s reactivity to drug cues, reducing the sensitivity to non-drug rewards, weakening self-
regulation, and increasing the sensitivity to stressful stimuli and dysphoria. Drug-induced impair-
ments are long lasting; thus, interventions designed to mitigate or even reverse them would be
beneficial for the treatment of addiction.The nature of addiction is frequently debated as either a per-
sonal ‘‘lifestyle choice’’ or a ‘‘biological vulnerability.’’ Current
evidence shows that most drugs of abuse exert their initial
reinforcing effects by activating reward circuits in the brain
and that, while initial drug experimentation is largely a voluntary
behavior, continued drug use impairs brain function by inter-
fering with the capacity to exert self-control over drug-taking
behaviors and rendering the brain more sensitive to stress
and negative moods. Indeed, individuals with genetic vulnera-
bilities, exposed to chronic stress, or suffering from comorbid
psychiatric conditions, as well as those who abused drugs
during early adolescence, are at greater risk of transitioning
into the automatic and compulsive behaviors that characterize
addiction.
Drugs modulate the expression of genes involved in neuro-
plasticity through epigenetic and possibly RNA modifications,
ultimately perturbing intracellular signaling cascades and
the neuronal circuits whose dysfunction have been implicated
in the long-lasting changes associated with addiction.
Here, we highlight some of the most significant and recent
findings in drug reward and addiction, describing the circuit,
behavioral, and synaptic mechanisms underlying this process.
Space limitations do not allow us to review the intracellular
signaling cascades and epigenetic modifications associated
with addiction; thus, we refer readers to recent reviews on
these topics (Heller et al., 2014; Nestler, 2012; Pascoli et al.,
2014a).
Drug Reward Signaling in Brain
Dopamine (DA) neurons located in the ventral tegmental area
(VTA) and projecting to the nucleus accumbens (NAc) play a
key role in the processing of reward-related stimuli, including
those associated with drugs of abuse (Wise, 2008). Drugs712 Cell 162, August 13, 2015 ª2015 Elsevier Inc.of abuse, through their different pharmacological effects, in-
crease the release of DA in the shell subregion of the NAc
(Di Chiara, 2002), mimicking the phasic DA neuronal firing
that leads to very fast DA increases (Owesson-White et al.,
2009) and thus the mechanism through which the brain signals
reward (Box 1). The large DA increases triggered by phasic
DA cell firing are necessary to stimulate D1 receptors (D1R)
in the NAc.
DA neurons in the VTA fire in either a tonic (1–8 Hz) or a tran-
sient (<500 ms) high-frequency phasic mode (>15 Hz), with the
phasic mode resulting in larger DA increases than the tonic
mode. Though it was initially believed that DA signaling in the
brain encoded for reward, more recent findings have revealed
that it encodes for a reward prediction signal. Specifically,
these studies have shown that phasic DA firing is time locked
to unexpected or novel reward but is also triggered by cues
that predict reward. Moreover, the firing frequency of DA neu-
rons triggered by cues is associated with the expected reward
value and its probability of delivery, but if the expected reward
does not materialize, DA cell firing is inhibited (Schultz, 2002).
Changes in the response patterns of DA cell firing are modu-
lated by more distinct projections for tonic than for phasic
firing (Box 1). Changes in phasic DA firing patterns modify
the strength of cortico-striatal glutamatergic synapses, thus
altering signaling in D1R- and D2R-expressing GABAergic me-
dium spiny neurons (MSNs) (Paladini and Roeper, 2014). This is
distinct from DA signaling in the NAc driven by release from
tonic DA neuron firing, which results in lower DA increases
than from phasic firing but that are sufficient to stimulate D2R
signaling and have been mostly associated with motivational
drive (Dreyer et al., 2010; Trifilieff et al., 2013). Though most
studies link drug-induced neuroplasticity with the fast and large
transient DA changes triggered by drugs, the contribution from
Box 1. Modulation of VTA DA Neuronal Firing
Recent pseudorabies virus-based methods for monosynaptic network
tracing have shown that neurons from many brain areas synapse on
distinct VTA DA neuron subpopulations (Lammel et al., 2014) and
that neurons from the dorsal raphe (DR) provide the majority of mono-
synaptic inputs (Ogawa et al., 2014). Studies of the influence of these
projections on DA neurons have been limited to a few brain structures
(Paladini and Roeper, 2014). For instance, the control of tonic firing of
VTA DA neurons involves the stria terminals and the ventral pallidum
(Georges and Aston-Jones, 2001; Mahler et al., 2014), whereas the
control of phasic firing of VTA DA neurons involves the pedunculo
pontine tegmentum (PPT), the subthalamic nucleus (STN), and the lat-
erodorsal tegmentum (Floresco et al., 2003; Lodge and Grace, 2006).
VTA DA neurons receive GABAergic innervation from local GABAegic
neurons, the NAc, globus pallidus, and rostromedial tegmental nu-
cleus, among others. These GABAergic projections are implicated in
the control of burst timing (Paladini and Roeper, 2014). It is likely that
phasic and tonic changes in DA neuronal firing triggered by repeated
drug administration, reflect neuroplastic changes in these regions
and on inputs that relay to them. For example, the lateral habenula
(LHb) indirectly inhibits VTA DA neurons via its inputs to GABA neurons
in rostromedial tegmental nucleus (Ji and Shepard, 2007), eliciting
aversion (Lammel et al., 2012), and these inputs are modified by
repeated cocaine administration (Meye et al., 2015). Thus, future
studies will be able to assess their contribution to the dysphoria and
enhanced stress reactivity in addiction.
We recently showed abundant glutamatergic projections from the DR
to VTA DA neurons that innervate the NAc, whose activation induced
DA release in NAc and evoked reward (Qi et al., 2014). The DR is
best known as a serotonergic structure that regulates emotional be-
haviors. However, findings on the role of DR serotonergic neurons in
reward have been inconsistent (Cohen et al., 2015; Fonseca et al.,
2015; Liu et al., 2014; McDevitt et al., 2014; Miyazaki et al., 2014),
which is likely to reflect, in part, the functional diversity of these neu-
rons. In this regard, cellular recordings from DR serotonergic neurons
in behaving mice have revealed that they convey reward information
through tonic as well as phasic firing and that they signal reward and
punishment on multiple timescales (Cohen et al., 2015). The DR also
has glutamatergic and GABAergic neurons, some of which co-release
serotonin, and thus future studies are necessary to tease apart the spe-
cific targets of the diverse serotonergic neurons and of their neigh-
boring GABAergic and glutamatergic neurons (Liu et al., 2014; McDe-
vitt et al., 2014; Qi et al., 2014). In this regard, we recently showed that,
within the VTA, DR neurons expressing the vesicular glutamate trans-
port (VGluT3) preferentially establish synapses on DA neurons (Qi et al.,
2014). These DR-VGluT3 neurons provide a major glutamatergic input
to VTA DA neurons, including those that innervate the NAc. Selective
activation of these DR-VGluT3 fibers results in VTA glutamate release,
NAc DA release, and reward (Qi et al., 2014). Notably, these DR
VGluT3-glutamatergic neurons (some of which may co-release seroto-
nin) are highly interactive with the serotonergic system (Commons,
2009). Thus, a better understanding of the function and connections
of the diverse DR neurons will help us determine whether they serve
as a link between reward and mood regulation and whether they
contribute to the high co-morbidity between drug use and depression.the longer-lasting stimulation of D2R (also D3R and D4R) has
been much less investigated.
VTA DA neurons project predominantly to the NAc, where DA
interacts with D1R, D2R, and D3R, which are mainly expressed
in MSNs. Stimulatory striatal MSNs that express D1R (D1R-MSNs) signal through the direct striatal pathway, whereas those
that express D2R (D2R-MSNs) signal through the striatal indirect
pathway and act in an inhibitory manner. D3R mostly co-localize
with D1R-MSNs, with which they heteromerize, potentiating their
function (Marcellino et al., 2008). The ventral striatal direct and in-
direct pathways have distinct roles in modulating reward and
motivation. The direct pathway is associated with reward,
whereas the indirect one is associated with punishment (Hikida
et al., 2010; Kravitz et al., 2012). Thus, DA receptor stimulation
of the direct pathway directly mediates reward, whereas DA-re-
ceptor-mediated inhibition of the indirect pathway opposes
aversive responses. This could explain why maximal drug
reward is obtained when DA binds to both D1R and D2R. How-
ever, in contrast to the situation in the dorsal striatum, where the
direct and indirect pathways are fully segregated, in the NAc,
both D1R- and D2R-expressing MSNs project into the ventral
globus pallidum (Smith et al., 2013b). To be reinforcing, drug-
induced DA increases need to be fast and sufficiently large to
stimulate low-affinity D1R in addition to D2R, leading to the acti-
vation of the direct pathway and the inhibition of the indirect
pathway. D1R stimulation in the NAc by itself is sufficient to pro-
duce drug reward (Caine et al., 2007), whereas D2R stimulation
is not (Caine et al., 2002; Durieux et al., 2009; Norman et al.,
2011), and maximal reward occurs when both D1R and D2R
are activated (Steinberg et al., 2014; Welter et al., 2007). Indeed,
brain imaging studies in humans have documented that fast DA
increases triggered by drugs are associated with the ‘‘high’’
associated with drug abuses, whereas stable DA increases are
not (Volkow et al., 2008). Specifically, when large DA increases
triggered by stimulant drugs were achieved over a short time
period (<10 min), they were associated with reward, whereas
DA increases achieved over 60 min were not. The rate depen-
dency for a drug’s rewarding effects might explain why the
time course of the subjective ‘‘high’’ is much shorter than the
longer-lasting DA increases triggered by drugs such as cocaine
and more notable methylphenidate (Figure 1). Presumably, stim-
ulation of D1 and D2R only occurs when drugs achieve fast peak
concentrations, whereas as the concentration of DA starts to
decrease, D2R are predominantly stimulated (Luo et al., 2011).
This may also explain why routes of administration that achieve
faster and higher drug levels in the brain, such as smoking and
intravenous injection, are more rewarding and addictive than
routes of administration that result in slow brain uptake, like
oral administration.
DA increases that are sufficiently large to activate D1R, such
as those induced by drugs in the NAc, can induce associative
learning, also referred to as conditioning (Zweifel et al., 2009).
Stimuli (including contextual or environmental) associated with
the drug become conditioned and, with repeated co-exposure,
will trigger phasic DA neuronal firing in the VTA, resulting in
fast, large, and short-lasting DA increases in the NAc. The DA in-
creases triggered by these conditioned stimuli (CS) are believed
to reflect the expectation of receiving a reward. Glutamatergic
projections into D1R-expressing MSNs coming from the amyg-
dala (involved in emotional reactivity), hippocampus (involved
in memory), and ventral PFC (involved in salience attribution)
mediate these conditioned responses. The increased dopami-
nergic signaling that follows exposure to the CS ensures thatCell 162, August 13, 2015 ª2015 Elsevier Inc. 713
Figure 1. Fast Brain Uptake and Fast DA Increases Triggered by
Drugs Are Necessary for Reward
(A) Pharmacokinetics of cocaine and methylphenidate (MPH) in the human
brain and relationship to the drug-induced ‘‘high.’’ Upper panels show axial
brain images of the distribution of [11C]cocaine and [11C]methylphenidate at
different time points (in minutes) following their intravenous administration.
Lower panels show time activity curves for the concentration of [11C]cocaine
and [11C]methylphenidate in the striatum in conjunction with the temporal
course of the ‘‘high’’ experienced after intravenous administration of the drug.
These findings suggest that the ‘‘high’’ is associated with the initial fast rate of
uptake of the drug in brain and presumably the associated fast DA increases
they trigger.
(B) Regression slopes between MPH-induced DA increase (assessed as the
reduction in the specific binding of [11C]raclopride to D2R and D3R) and the
self-reports of ‘‘high’’ when MPH was administered intravenously, which re-
sults in very fast drug delivery in the brain (measures initiated at 1 min post
MPH) and when MPH was administered orally, which results in very slow brain
uptake (measures initiated at 60 min post MPH). MPH-induced DA increases
resulted in a ‘‘high’’ only when it was given intravenously, but not when given
orally, consistent with fast DA increases being necessary for drug reward.
Figure modified from Volkow et al., 1995, 1999, 2001b.
Box 2. Opioid Regulation of the Mesolimbic DA Pathway
Endogenous opioids modulate DA neuronal firing in midbrain (Margolis
et al., 2014) and striatal MSNs (Gianoulakis, 2009), where dynorphin
co-localizes in D1R-MSNs and enkephalin in D2R-MSNs (Gerfen
et al., 1990). Endogenous opioids are implicated in hedonic responses
to natural and drug rewards (Le Merrer et al., 2009) and also in the ad-
aptations that follow repeated drug exposures and drug relapse (Koob
et al., 2014).
Microdialysis studies measuring the effects of various drug classes
(including stimulants, opiates, THC, and alcohol) have found in-
creases in extracellular levels of endogenous opioids in the NAc
and VTA (reviewed in Murphy, 2015). The roles of endogenous opioids
in drug reward are particularly well established for alcohol and opi-
ates, whose intake is reduced in mu opioid receptor (MOR) knockout
mice and decreased by administration of opioid receptor antagonists
(reviewed in Tseng et al., 2013). Moreover, naltrexone, an opiate
antagonist, is an FDA-approved medication for the treatment of alco-
holism and opiate use disorders. In animal models, MOR antagonists
interfere with cocaine and nicotine reward (Berrendero et al., 2010;
Giuliano et al., 2013); however, clinical trials with naltrexone have
failed to show therapeutic benefit for cocaine or nicotine use
disorders.
The endogenous opioid system also contributes to the effects of
stress on drug consumption. Specifically, dynorphin, through its acti-
vation of kappa receptors (KOR), is implicated in the stress-induced
potentiation of drug reward (reviewed in Ehrich et al., 2014). Activation
of KOR on DA terminals inhibits DA release in the NAc, which is impli-
cated in the dysphoria that follows drug withdrawal (Tejeda et al.,
2012). These findings have generated interest in KOR antagonists
or partial agonists as medications to prevent relapse in addiction
(Al-Hasani et al., 2013; Butelman et al., 2012; Grosshans et al., 2015;
Schlosburg et al., 2013; Smith et al., 2013a).
The effects of drugs on the opioid system in the human brain have
been investigated with positron emission tomography (PET) using
[11C]carfentanil to assess MOR and their occupancy by enkephalins.
These studies have shown that acute alcohol, but not intravenous
amphetamine, increases enkephalins (Guterstam et al., 2013; Mitchell
et al., 2012). Increases in enkephalins after cigarette smoking have
been inconsistent, which is likely to reflect, in part, the influence of
MOR gene variants in these responses. More specifically, increases
were observed only in smokers with the AA variant of the MOR
A118G polymorphism (Domino et al., 2015).
Brain-imaging studies ofMOR in alcoholics and cocaine abusers have
reported increased [11C]carfentanil binding, which has been inter-
preted to reflect reduced levels of endogenous enkephalins (hence,
decreased competition for ligand binding) though they could also
reflect MOR upregulation (Weerts et al., 2011; Zubieta et al., 1996).
In cocaine abusers, the increases in [11C]carfentanil binding have
been associated with worse clinical outcomes (reviewed in Volkow,
2010). In contrast, studies in smokers have shown no changes in
[11C]carfentanil binding (Kuwabara et al., 2014).
Brain-imaging studies of delta opioid receptors in alcoholics
(measuredwith PET and [11C]methylnaltrindole) showed no differences
when compared to controls (Weerts et al., 2011). To our knowledge, no
PET studies have been done in substance abusers using kappa recep-
tor ligands.the individual will have the motivation to engage in the behaviors
necessary to procure the reinforcer, be it natural or pharmaco-
logical. Because D1R have a lower affinity for DA than D2R,
cue exposure or drug intoxication will lead to D1R occupancy
only when peak DA levels are present; all the while, DA binding
to D2R will be longer-lasting and persist even after peak levels
have subsided (Luo et al., 2011). Thus, while DA stimulation of
D1R-MSNs in the direct pathway signals the expectation for
the reward, DA stimulation of D2R-MSNs in the indirect pathway
is more likely to sustain the motivation needed to procure and
consume the reinforcer.
For natural reinforcers such as food or sex, the DA signals
triggered by the CS drive the motivation to get the reward since
with their repeated delivery the DA cells stop firing in response
to their consumption (Schultz et al., 1997). This is in sharp
contrast to the response to drugs of abuse, which due to their
pharmacological properties, continue increasing DA release
during their consumption. Thus, DA in the NAc will increase
upon exposure to drug cues, which will trigger the desire to
take the drug (craving) also during their consumption, which
will sustain the motivation to continue consuming them. This
may explain why drugs are more likely to result in compulsive
patterns of administration than natural reinforcers. However,714 Cell 162, August 13, 2015 ª2015 Elsevier Inc.the DA increases triggered by cocaine, and presumably other
drugs, activate D2R auto-receptors inhibiting DA cell firing
and DA release (Bello et al., 2011), which is perhaps why the
intensity of the cocaine ‘‘high’’ is reduced with subsequent
Figure 2. Drug-Induced Synaptic Neuro-
plasticity in Brain Reward Circuitry
Mesocorticolimbic brain areas where there is evi-
dence of drug-induced neuroplasticity along with
the associated synaptic modifications and their
behavioral consequences. AMG, amygdala; NAc,
nucleus accumbens; (m)PFC, (medial) prefrontal
cortex; VTA, ventral tegmental area; CRFR, corti-
cotropin releasing factor. Figuremodified from van
Huijstee and Mansvelder (2014) and work from
Krishnan et al. (2010) and Lee et al. (2013).administrations, whereas the motivation to continue to take the
drug continues unabated.
Endogenous opioids and cannabinoids have been also impli-
cated in drug reward responses, in part through the opioid regu-
lation of themesolimbic DA pathway (Box 2) and through studies
of the role of cannabinoids in adaptations that occur with
repeated drug exposures (for reviews, see Covey et al., 2014;
Panagis et al., 2014).
Transition into Addiction
The ability of drugs to increase DA in the NAc and trigger condi-
tioned responses in both naive and addicted individuals indi-
cates that changes in DA levels alone cannot account for the
addiction phenotype. Importantly, addiction seems to emerge
gradually, although the rate of this transition varies as a func-
tion of several factors, including the type of drug (i.e., faster
for methamphetamine and slower for cannabinoids), the
pattern of exposure (greater for regular than occasional use),
and the developmental stage (faster in adolescence than in
adulthood) (Robins and Przybeck, 1985; Schramm-Sapyta
et al., 2009). The transition from controlled to compulsive
drug taking has been associated with a shift in the involvement
of striatal subregions (NAc), implicated in the rewarding
response to drugs, to the dorsal striatum that is associated
with habit formation (Everitt and Robbins, 2013). The speed
with which addiction emerges is influenced by genetics, with
some individuals transitioning faster than others due to genetic
vulnerabilities (Kessler et al., 2007). To properly emulate the
addiction phenotype, animal models of human addiction must
feature compulsive drug consumption that occurs in spite of
adverse consequences (Piazza and Deroche-Gamonet, 2013).
This is because a characteristic of addiction is the failure
of the individual to control his/her drug consumption despite
catastrophic adverse consequences (i.e., incarceration or
loss of job or child custody). Interestingly, in such models,
only 10% of experimental animals will develop an addiction
phenotype, which is similar to the estimated percentage of
drug-exposed individuals who become addicted (Seedall and
Anthony, 2013).Cell 162The pharmacological mechanisms of
action of various drugs types influence
the nature of the molecular and cellular
changes associated with their repeated
consumption. For example, alpha 6 and
beta 3 nicotinic receptors are upregu-
lated in DA neurons with repeated nico-tine exposure (Visanji et al., 2006), dopamine transporters are
downregulated in the striatum with repeated methamphetamine
exposure (Groman et al., 2012), and cannabinoid receptors 1 are
downregulated in striatum with repeated delta9-tetrahydrocan-
nabinol (THC) exposure (Romero et al., 1997). These changes
are likely to contribute to the emergence of tolerance to the
drug’s effects and the need to use increasingly larger doses in
an attempt to achieve the same behavioral effect. In turn, expo-
sure to higher drug doses facilitates the neuroplastic changes
that ultimately change the reactivity of brain DA pathways to
drugs and drug cues.
Drug-Induced Neuroplasticity in DA Pathways
Drug-induced DA increases trigger various forms of synaptic
plasticity that can result in strengthening or weakening of synap-
tic connectivity in various brain reward regions (Figure 2 and
Box 3) (Grueter et al., 2012). These drug-induced neuroplastic
changes largely hinge on the epigenetic enhancement or
silencing of gene expression and on epitranscriptomic (RNA edit-
ing)modulation of translation, twomechanismswhosedetails are
beginning to be uncovered (Kenny, 2014; Robison and Nestler,
2011; Satterlee et al., 2014). Among the transcription factors
implicated in the long-lasting neuroplastic changes that follow
repeated drug exposure is DFosB (Maze et al., 2010). Drug-
induced neuroplasticity evokes the same types of molecular pro-
cesses involved in long-term potentiation (LTP) and long-term
depression (LTD) that underlie learning and memory. The
changes in synaptic strength that occur as a result of LTP are
associated with larger synapses and dendritic spines, while
those that follow LTD involve smaller synapses and dendritic
spines (De Roo et al., 2008). These synaptic modifications
generate a long-lasting molecular memory for the drug’s
rewarding and conditioning effects that will modify subsequent
behaviors (Hyman, 2005).
Most of the studies of neuroplasticity have investigated the
effects of chronic cocaine in the NAc (Sesack and Grace,
2010). Chronic cocaine increases dendritic spine density in
MSNs (Russo et al., 2010), and DFosB is implicated in their gen-
eration (Maze et al., 2010). The structural changes observed in, August 13, 2015 ª2015 Elsevier Inc. 715
Figure 3. Drug-Induced Reductions in Striatal D2R Are Associated
with Decreased Activity in Prefrontal Cortex
(A) Schematic representation of the indirect pathways in which DA neurons
from the ventral tegmental area (VTA) and the substantia nigra compacta (SN)
provide DA inputs to the striatal GABA neurons expressing D2R (D2R-MSNs).
These striatal neurons target GABA cells in the globus pallidum external (GPe),
which provide inhibition to glutamatergic neurons within the subthalamic nu-
cleus (STN). The STN glutamatergic neurons provide an excitatory input to
GABA neurons present in the substantia nigra reticulata (SNR) and the globus
pallidum internal (Gpi), which inhibit glutamate neurons of the thalamus
innervating the frontal cortex. Drug-induced reductions in D2R within the
striatum impair the inhibition of this indirect pathway by DA, resulting in
reduced thalamo-cortical stimulation and consequently reduced activity in the
frontal cortex.
(B) Relationship between D2R in striatum and brain glucose metabolism in
frontal regions of drug abusers tested both with [11C]raclopride and FDG.
Images next to the y axis show axial brain metabolic images at the level of the
orbitofrontal cortex, and images below the x axis show axial images of D2R
striatal availability for a control and a cocaine abuser. Regression slopes
correspond to the association between metabolism in the orbitofrontal cortex
(OFC) and D2R availability in striatum in cocaine-addicted and in metham-
phetamine-addicted subjects.
Figure modified from Volkow et al., 2011.
Box 3. Synaptic Plasticity in DA Circuits
Many drugs of abuse, including cocaine, but also morphine, nicotine,
and ethanol, can evoke synaptic plasticity in VTA DA neurons (Bowers
et al., 2010; Lu¨scher andMalenka, 2011). Because VTADA neurons are
heterogeneous in their synaptic connectivity, molecular composition,
and electrophysiological and signaling properties (Lammel et al.,
2014), it is conceivable that drugs differentially affect their subpopula-
tions. For instance, VTA DA neurons that lack DAT or D2R (Li et al.,
2013) innervate the medial PFC, but not the NAc (Bannon and Roth,
1983; Lammel et al., 2012; Sesack and Grace, 2010). Moreover,
some of the VTA DA neurons innervating the NAc have axons with mi-
cro-domains for either DA or glutamate signaling, further emphasizing
their diversity (Zhang et al., 2015).
DA regulates excitatory synaptic plasticity both by increasing and
decreasing synaptic strength through LTP and LTD. Synaptic strength
is controlled by the insertion or removal of AMPAR or NMDAR and by
changes in the subunit composition of AMPA receptors. Specifically,
the insertion of high-calcium permeable AMPAR (GluR2 subunit) con-
tributes to the drug-induced increases in AMPAR-to-NMDAR ratios
associated with LTP in models of addiction (Boudreau et al., 2007;
Conrad et al., 2008; Kourrich et al., 2007). These AMPAR have higher
single-channel conductance than GluA2-containing receptors (Guire
et al., 2008; Liu and Cull-Candy, 2000), and their upregulation in-
creases the responsiveness of MSNs in the NAc to glutamate released
by cortical and limbic terminals when exposed to drugs or drug cues
(Wolf and Ferrario, 2010). Drug-induced neuroplastic changes have
been uncovered in glutamatergic inputs to the NAc from PFC, basolat-
eral amygdala, and ventral hippocampus (Figure 2) (Di Forti et al., 2014;
Lee and Dong, 2011; MacAskill et al., 2014; Pascoli et al., 2014b).
Recently, the use of genetic cellular tagging has enabled researchers
to identify the clusters of neurons within the PFC that trigger excitatory
signals into NAc with exposure to cocaine cues (Cruz et al., 2014).
Though not as extensively investigated as theNAc, the dorsal striatum
also undergoes neuroplastic changes with repeated cocaine expo-
sure; these are implicated in habit learning and in the automatic
cocaine consumption triggered by repeated cocaine exposures (Ever-
itt et al., 2008; Hearing et al., 2011; Lavaur et al., 2009; Parikh et al.,
2014).dendritic spines involve cytoskeletal and actin-myosin rear-
rangements and other structural proteins that regulate spine
morphology and dendritic arborization (Toda et al., 2006). In
addition, the formation of new spines is preceded by the gener-
ation of ‘‘silent’’ synapses containing NMDARs, but not
AMPARs (Huang et al., 2009; Malenka and Nicoll, 1997), which
are subsequently unsilenced through the insertion of AMPAR
lacking GluA2 (Box 3)(Conrad et al., 2008; Dobi et al., 2011).
Role of Dopamine in Addiction
Repeated exposure to different types of drugs has been associ-
ated with downregulation of D2R in striatum (Nader et al., 2006;
Thanos et al., 2001; Volkow et al., 2001a). Specifically, studies in
rodents and non-human primates have found reduced levels of
D2R in the striatum, including in the NAc, upon chronic drug ex-
posures, as well as in animals with a propensity to self-admin-
ister drugs (Everitt et al., 2008). In rodents, low levels of D2R in
striatum are associated with impulsivity and predict escalating
and compulsive administration of cocaine (Everitt et al., 2008).
Similarly, human brain-imaging studies of addicted individuals716 Cell 162, August 13, 2015 ª2015 Elsevier Inc.have shown reductions in D2R availability in ventral and dorsal
striatum for most of the drugs, except for marijuana (reviewed
in Volkow and Baler, 2014). Low levels of D2R in the striatum
will result in reduced DA inhibition of the indirect pathway. D2R
have high affinity for DA, so they are stimulated by the relatively
low DA levels achieved through tonic DA cell firing. Reduced
D2R-mediated DA inhibition of the indirect pathway will lead to
reduced thalamo-cortical stimulation and consequently reduced
activity in PFC brain regions (Figure 3) (Black et al., 2010).
Indeed, the reductions in striatal D2R (dorsal and ventral) in
drug abusers have been associated with decreased activity in
the PFC, including anterior cingulate (ACC) and orbitofrontal
(OFC) cortical regions. The ACC and OFC are necessary for
self-control and for processing salience attribution, and their
disruption is associated with a propensity for impulsive and
compulsive behaviors (Volkow and Fowler, 2000). Thus, low
levels of D2R in striatum may mediate the risk for compulsive
drug taking in part by impairing PFC regions that inhibit prepo-
tent responses and enable flexibility of behavioral choices as a
function of changing environments (Volkow et al., 2006a).
Figure 4. Stimulant-Induced Dopamine Increases Are Blunted in
Active Cocaine Users
(A) Brain maps of normal controls (left) and active cocaine abusers (right)
showing DA increases in the striatum after methylphenidate (MPH) adminis-
tration reveal a robust response in controls, but not in cocaine abusers.
(B) Correlation between MPH-induced DA increases (measured as changes in
non-displaceable binding potentials or BPND) in ventral striatum (where NAc is
located) and the changes in craving scores (cocaine craving questionnaire
[CCS]).
Figure modified from Volkow et al., 2014a.Indeed, in rodents, optogenetic stimulation of the PFC prevented
cocaine relapse (Chen et al., 2013). In contrast to the findings of
low striatal D2R in addicted individuals, which in laboratory ani-
mals is associated with vulnerability for compulsive cocaine
intake, the chemogenetic stimulation of D2R-MSNs (perhaps
somewhat akin to lack of DA inhibition through D2R) has been
shown to inhibit cocaine intake in mice (Bock et al., 2013). This
seemingly paradoxical finding suggests that the low D2R levels
in addicted individuals may reflect reduced postsynaptic and
presynaptic receptors and that the firing of D2R-MSNs is not
only modulated by D2R, but also by NMDAR, AMPAR, GABAR,
A2AR, and CB1R among other receptors. Thus, low D2R levels
are likely to unbalance DA’s modulation of the indirect pathway,
whereas the chemogenetic inhibition of D2R-MSNs interrupts
the signaling in this circuit. In this regard, it is interesting to
note that D2R agonists tend to decrease cocaine intake rather
than increase it, as seen with the chemogenetic inhibition of
D2R-MSNs.
Though, theoretically, enhanced signaling through D1R and its
activation of the direct pathway would be consistent with facilita-
tion of drug reward (Gore and Zweifel, 2013), the findings related
to the consequences of repeated drug exposure on D1R have
not been consistent. Thus, whereas some studies have shown
that chronic cocaine potentiated D1R signaling (Pascoli et al.,
2012), others have reported decreased D1R excitability (Kim
et al., 2011), and while in nonhuman primates repeated cocaine
exposure was associated with reductions in D1R in striatum
(Moore et al., 1998), human studies failed to observe this effect
(Martinez et al., 2009).
D1R-MSNs and D2R-MSNs do not fire independently of each
other, and during drug exposure, enhanced DA signaling will
stimulate one population but inhibit the other. Thus, it is likely
that the balance between striatal signaling through the direct
(D1R-mediated) and the indirect (D2R-mediated) pathways un-
derlies drug responses and that an imbalance between these
pathways may ultimately underlie the behavioral changes
observed in addiction. In fact, we have recently shown that, dur-
ing acute cocaine intoxication, signaling through both D1R and
D2R in the striatum was markedly reduced in mice previously
exposed to chronic cocaine, although the attenuation was
greater for D2R than for D1R (Park et al., 2013). As a result, DA
signaling though D1R versus D2R was biased in favor of DA-
mediated D1R signaling during the state of intoxication (Park
et al., 2013). Since DA stimulation of D1R is associated with
enhanced sensitivity to drug reward, a higher D1R-to-D2R
signaling ratio during drug intoxication could contribute to
compulsive drug taking. The D3Rs, which are highly expressed
in the mesolimbic DA system, have also been implicated in the
transition to addiction, and D3R antagonists have been pro-
posed as promising targets for the development of addiction
treatments (Heidbreder and Newman, 2010). D3R in the NAc
are upregulated by chronic cocaine (Conrad et al., 2010),
whereas D3R blockade interferes with cocaine reward (Heid-
breder and Newman, 2010). In humans, imaging and postmor-
tem studies have found an upregulation of D3R in the NAc of
cocaine abusers (Payer et al., 2014; Staley and Mash, 1996).
However, findings in mice expressing no D3R (D3R KO mice)
have been equivocal, with one study showing that D3R KO ani-mals display enhanced motivation for cocaine-seeking behavior
(Song et al., 2012) and another showing no effect on motivation
(Caine et al., 2012).
A powerful approach for investigating changes in DA signaling
in addiction is to compare the DA responses triggered by drugs
in addicted versus non-addicted individuals. PET studies have
made it possible to measure drug-induced DA increases in
humans (Volkow et al., 1994)—for instance, in studies that
compared the effects of drug intoxication between cocaine
abusers and controls, where stimulant drugs such asmethylphe-
nidate and amphetamine were used as pharmacological
challenges. These studies have consistently shown that the DA
increases triggered by stimulants are markedly attenuated in
cocaine abusers, both in dorsal and ventral striatal regions
(reviewed in Volkow et al., 2014a). These blunted responses
are consistent with preclinical findings showing reduced DA
signaling during cocaine intoxication in mice chronically
exposed to cocaine (Park et al., 2013). Despite these markedly
blunted DA responses, the DA increases in NAc were associated
with drug-induced craving (Volkow et al., 2014a) (Figure 4). In
cocaine abusers (Martinez et al., 2011) and in methamphetamine
abusers undergoing substance abuse treatment (Wang et al.,
2012), the blunted DA responses to stimulant drugs have been
also associated with worse clinical outcomes. Studies in alco-
holics have further documented blunted DA increases upon
challenge with a stimulant drug, which are consistent with
reduced DA cell activity (Martinez et al., 2005; Volkow et al.,
2007), but have also uncovered increased brain reactivity to
the DA increases, which suggests impaired downstream modu-
lation (Martinez et al., 2005; Volkow et al., 2007, 2013). In
contrast, in marijuana abusers, while stimulant-induced DA
increases in striatum did not differ from controls (Urban et al.,
2012; Volkow et al., 2014b), the brain reactivity to DA stimulation
was blunted, an effect that was associated with negative
emotionality (Volkow et al., 2014b). Similarly, a PET study
using 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine ([18F]-DOPA)
reported that the reduced striatal DA synthesis capacityCell 162, August 13, 2015 ª2015 Elsevier Inc. 717
Box 4. The ‘‘Dark Side of Addiction’’
The ‘‘dark side of addiction’’ involves allostatic changes that lead to
drug use as a means to counteract the dysphoria and distress associ-
ated with drug withdrawal and discontinuation. Studies implicate the
extended amygdala (central nucleus of the amygdala, bed nucleus of
the stria terminalis, and a transition area in the NAc shell), cortico-
tropin-releasing factor (CRF), and norepinephrine in these allostatic
responses (Koob, 2013). Upregulation of the dynorphin/kappa opioid
receptor system has also been associated with the dysphoria and
the increased sensitivity to stress during drug discontinuation (see
also Box 2). In parallel, downregulation of signaling though neurotrans-
mitters associated with positive rewards, including DA, enkephalins
(Zubieta et al., 1996), endocannabinoids (Serrano and Parsons,
2011), and the reduced DA inhibition through D2R of the indirect
pathway, which signals aversive responses (Danjo et al., 2014), might
also contribute to dysphoria in addiction.
Recently, studies have identified the lateral habenula (LHb) as a brain
region disrupted by drugs that might also contribute to the dark side of
addiction (Velasquez et al., 2014). The LHb, through its projection to
the rostromedial tegmental nucleus, can inhibit DA cell firing (Ji and
Shepard, 2007). The LHb is activated upon exposure to unrequited
expectation and aversive stimuli, which could therefore also contribute
to the enhanced sensitivity to stress in addiction.
Humans display activation in both the VTA and the habenula in
response to aversive events (Hennigan et al., 2015). We had found
that diverse VTA cellular phenotypes, which may be involved in
different behaviors, synapse on LHb neurons (Root et al., 2014b).
This synaptic complexity is reflected in behavioral studies showing
that LHb photo-activation of some fibers from the VTA evokes reward
(Stamatakis et al., 2013), while activation of others evokes aversion
(Hennigan et al., 2015; Root et al., 2014a). The LHb synaptic
complexity provided by VTA is not surprising, as multiple streams of in-
formation may be encoded and decoded by the different types of VTA
cells and their corresponding efferent to downstream brain targets.observed in marijuana abusers was associated with apathy and
amotivation (Bloomfield et al., 2014).
The regional brain activation responses to a stimulant drug
also differ between controls and cocaine abusers in ventral pre-
frontal regions. In control subjects, intravenous stimulant admin-
istration decreased the activity of ventral medial frontal regions
(OFC and ventral ACC), whereas in cocaine abusers, it activated
these regions, which are involved in salience attribution and con-
ditioning (Dosenbach et al., 2006; O’Doherty et al., 2001; Shack-
man et al., 2011). Activation of the OFC in cocaine abusers was
associated with craving (Volkow et al., 2005). In contrast, activity
in the right inferior frontal region Ba 44, a key brain region
involved in inhibitory control (Aron et al., 2004), was associated
with the deactivation of the NAc and ventral PFC upon success-
ful control of cocaine craving (Volkow et al., 2010). This pattern of
responses uncovers distinct contributions of PFC regions to
addiction on the basis of their striatal projections: dlPFC and
inferior frontal regions that project to the dorsal caudate facilitate
self-control, whereas ventral PFC regions projecting to NAc facil-
itate drug taking (Goldstein and Volkow, 2011). This is also
consistent with preclinical findings that identified distinct contri-
butions of prelimbic mPFC (PL) and infralimbic mPFC (IL) to
cocaine seeking in rats (review in Bossert et al., 2013). Studies
using the reinstatement model of relapse found that, after extinc-718 Cell 162, August 13, 2015 ª2015 Elsevier Inc.tion of cocaine self-administration, PL activity promoted cocaine
seeking while IL activity inhibited it (Peters et al., 2008). Impor-
tantly, in the incubation of the cocaine-craving model (response
to cocaine cues progressively increases with time after with-
drawal), reversible inactivation of IL, but not PL, decreased
‘‘incubated’’ cue-induced cocaine seeking after prolonged with-
drawal, while pharmacological activation of IL, but not PL,
increased cocaine seeking during early withdrawal (Koya et al.,
2009). However, in the same animal model, optogenetic inhibi-
tion of PL neurons (projecting to NAc core) that previously under-
went a specific form of cocaine-induced synaptic plasticity
(recruitment of silent synapse) decreased incubation of craving,
while the opposite effect was observed following inhibition of the
IL projection to NAc shell (Di Forti et al., 2014). In clear contrast,
in a punishment-induced suppression model of ‘‘compulsive’’
cocaine seeking, in which most rats suppressed cocaine self-
administration by shock punishment while a few did not (punish-
ment-resistant ‘‘compulsive’’ rats), optogenetic stimulation of PL
inhibited cocaine seeking in punishment-resistant rats while op-
togenetic inhibition increased it (Chen et al., 2013). However, in
the same model, excitotoxic lesions of the PL or IL had no
detectable effect on cocaine seeking in punishment-resistant
rats (Pelloux et al., 2013). Taken together, the PL and IL appear
to play different and complex roles in cocaine-seeking behaviors
in rat addiction models, which are highly dependent on the
particular behavior being assessed and the experimental proce-
dure used to manipulate local neuronal activity. The results un-
derscore the complexity of the neuroplasticity within the mPFC
circuitry, a multimodal brain structure involved in the orchestra-
tion of diverse behaviors.
The regional brain responses to drug-associated cues have
also been investigated with neuroimaging. These studies have
shown that, in cocaine abusers, exposure to cocaine cues trig-
gers DA release in the dorsal striatum and that this effect was
associated with craving (Volkow et al., 2006b; Wong et al.,
2006). Interestingly, similar increases were not observed in to-
bacco smokers upon exposure to nicotine cues (Chiuccariello
et al., 2013), whereas exposure to alcohol cues in healthy con-
trols resulted in DA decreases (Yoder et al., 2009). Studies with
fMRI have shown, more or less consistently, that exposure to
cues in substance abusers is associated with increased activa-
tion of NAc and VTA (Goudriaan et al., 2013), which most likely
reflects not only cue-induced DA increases, but also excitatory
stimulation stemming from glutamatergic terminals into NAc
and midbrain. These studies have also identified several other
regions that are co-activated during cue exposure, including
the PFC, cerebellum, limbic regions, and insula (Jasinska et al.,
2014). Activation of the insula is noteworthy since this region is
involved in interoceptive awareness, contributes to the
conscious awareness of drug craving, and is part of the default
mode network (DMN) that enables internal mind wandering,
perhaps facilitating rumination about drug use in addicted sub-
jects (Naqvi and Bechara, 2010).
Neuronal Circuitry in Addiction
The use of imaging tools to study changes in the brains of in-
dividuals suffering from addictions has helped to identify the
brain regions and associated circuits that are disrupted and
Figure 5. Neuronal Circuitry of Addiction
Proposed neuronal network of interacting brain regions and associated cir-
cuits that are disrupted in addicted individuals. Changes occur in reward (NAc
and VTA), conditioning/memory (amygdala and medial OFC for emotional and
salience attribution; hippocampus and dorsal striatum for memories and
habits), executive control (ACC, inferior PFC, dlPFC, and lateral OFC), moti-
vation/drive (medial OFC for attribution of salience, ventral ACC, VTA, dorsal
striatum, NAc), interoception (insula and ACC), and aversion/avoidance
(habenula). This model proposes that, during addiction, the enhanced
expectation value of the drug in the reward, motivation, and memory circuits
overrides the control circuits, favoring a positive-feedback loop initiated by
consumption of the drug and perpetuated by the enhanced activation of the
motivation/drive and memory circuits. These circuits also interact with those
involved in mood regulation, including stress reactivity (which includes
participation of the extended amygdala, hypothalamus, and habenula)
and interoception (which includes participation of the insula, ACC, and the
default mode network [DMN] and contributes to a heightened awareness
of craving). NAc, nucleus accumbens; VTA, ventral tegmental area; PFC,
prefrontal cortex; OFC, orbitofrontal cortex; ACC, anterior cingulate cortex;
dlPFC, dorsolateral PFC.
Box 5. Translational Opportunities
d Enhance tonic dopaminergic D2R signaling through the indirect
pathway to improve control. Pharmacologically, this is challenging
because currently available D2R agonists (or partial agonists) also
bind to D3R, and stimulation of D3R has been associated with
impaired impulse-control disorders (Seeman, 2015).
d Enhance function of prefrontal regions involved in executive func-
tion, including self-control via transcranial magnetic or electrical
stimulation, mindfulness, or other behavioral interventions, and
through medications that increase DA signaling in prefrontal re-
gions (i.e., tomoxetine, oral stimulants, modafinil).
d Decrease the reactivity of stress-associated circuits (extended
amygdala, habenula) through the use of biofeedback or medica-
tions (CRF or kappa antagonists)
d Decrease the motivation value of conditioned responses to drug
cues (by targeting PFC, amygdala, hippocampus) through the
use of behavioral extinction interventions, including coupling inter-
ventions with medications (i.e., d-cycloserine).
d Reduce dysphoria and enhance hedonic responses to non-drug
rewards during withdrawal and drug discontinuation though the
use of cognitive behavioral interventions or medications.understand how these changes influence behaviors associated
with the addiction phenotype. These studies have revealed
changes in reward and motivation, resulting in increased moti-
vation toward drugs and drug cues and in decreased motiva-
tion for non-drug reward and cues, executive control, resulting
in reduced ability to control the urge to take the drug, triggered
by cues, emotional states, or an impaired ability to delay grat-
ification, as well as mood and interoceptive circuits, resulting
in an enhanced sensitivity to stressors and dysphoria or the
so-called ‘‘dark side of addiction’’ (Box 4 and Figure 5; Koob,
2013).
In this model of addiction, themotivation to take the drug is not
only driven by conditioned responses to cues, but also by nega-
tive emotional states. The exposure to drug cues results in the
activation of glutamatergic projections from the ventral PFC,
the ventral hippocampus, and the amygdala (and presumably
medial thalamus) to striatal projections that increase DA
signaling and release in the NAc and dorsal striatum. The
enhanced craving and desire for drug taking will eventually
lead to drug consumption, and although the drug-induced DA in-
creases are markedly attenuated in the NAc, in particular of
cocaine abusers and alcoholics, they are sufficient to enhance
the craving and to sustain the drive to continue taking the drug
(Figure 4), perhaps by stimulation of upregulated D3R that facil-
itate transmission through the D1R direct pathway (Fiorentiniet al., 2010). The ventromedial PFC (including OFC and ventral
ACC) in drug-addicted individuals, which in the absence of
drug or drug cues is hypofunctional, becomes hyperactive
when exposed to drugs or cues, enhancing reward salience
calculation through its involvement in the processing of the
outcome value of that reward (Volkow et al., 1996).
The control circuit, which relies on the PFC, including ACC,
lateral OFC, dlPFC, and the inferior frontal cortex (BA 44), is dis-
rupted in addicted individuals. The reduction in D2R signaling in
the striatum leads to reduced activity in these PFC regions
(Figure 3), which is necessary for proper control, planning, and
flexibility of behaviors and for delaying gratification (Volkow
and Baler, 2015). Specifically, the OFC is critically involved in
salience attribution; its main contribution is to offer predictive in-
formation about alternative options and outcomes, which is
essential for shifting behaviors when the reward is no longer re-
inforcing. Meanwhile, the ACC enables inhibitory learning by
keeping tabs on conflicts between predicted and actual out-
comes and by conveying that information to inhibitory circuits
orchestrated by the dlPFC, the inferior frontal regions (BA 44),
and the dorsal caudate. This inhibitory arm of the decision-mak-
ing process is facilitated, in turn, by tonic DA signaling sustaining
activity in ACC, dlPFC, and inferior PFC. Together with the OFC,
the insular cortex and the ACC also allow the circuit to estimate
the level of uncertainty involved in choosing among alternative
options. Finally, the extended amygdala, insula, and lateral ha-
benula, which provide information about emotional salience,
interoceptive awareness, and pertinent reward omission events,
respectively, contribute to dysphoria, anhedonia, and the
enhanced stress reactivity that follows drug withdrawal (Koob
and Le Moal, 2005).
In consequence, the addicted individual experiences
enhanced reactivity to drug cues and to stressful stimuli, the
reactivity to natural reward is decreased, and there is loss of flex-
ibility to adjust the saliency value of reward as a function of their
context. Although the neuronal adaptations that follow repeatedCell 162, August 13, 2015 ª2015 Elsevier Inc. 719
Box 6. Perspectives in Reward Circuitry and Addiction
Identification of DA neuron subtypes in VTA and SN and character-
ization of their projections, inputs, and function.
Investigation of interactions between the nuclei and circuits medi-
ating reward and those involved with mood regulation, including
those with the dorsal raphe.
Investigation of the dynamic interactions between coordinated
pathways (for instance, the direct and indirect MSNs pathways)
in drug reward and in compulsive drug taking.
Investigation of the neurocircuitry that drives ‘‘antireward’’ and the
dark side of addiction (Koob et al., 2014), including the role of the
habenula and kappa/dynorphin signaling.
Investigation of how genes influence the molecular biology and
neurocircuitry that underlies individual heterogeneity in vulnera-
bility and resilience to addiction.
Identification of biomarkers that can be used to personalize pre-
vention and therapeutic interventions in substance use disorders.drug exposures are not fully understood, the picture that is
emerging of the drug-induced neuronal impairments is already
helping us to think about interventions that could remediate
them through the development of medications/immunother-
apies, magnetic or electrical stimulation strategies, and/or
behavioral approaches (Box 5). The development of such inter-
ventions will benefit from an understanding of the specific cir-
cuitry or functional processes being targeted, rather than using
abstinence as the only beneficial outcome in addiction treat-
ment. For example, interventions designed to counteract
dysphoria or strengthen executive control, even if not resulting
in complete abstinence, may improve long-term success and
recovery from addiction. In parallel, these neurobiological ad-
vances have begun to reveal the molecular and neuronal bases
underlying the heterogeneity of the clinical presentation and
the outcomes of addicted individuals (Box 6). In the near future,
these advances might enable the development of tailored thera-
peutic interventions on the basis of the specificmolecular targets
and/or circuits disrupted in a given individual.
In conclusion, uncovering the neurobiology underlying drug
abuse has led to the recognition of addiction as a chronic dis-
ease of the brain. At the same time, these advances have
revealed potential targets for interventions that could usher in
a new era of more effective and personalized addiction
treatments.REFERENCES
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